Movement Alert｜Kelun-Biotech Falls 3.45% in Regular Trading, Profit-Taking After Prior Session Clinical Data Rally

Market Focus07-16

On July 16, Kelun-Biotech (06990.HK) declined 3.45% in regular trading, trading at HK$519.5/share, with turnover of HK$125 million. The stock opened up over 4% before rapidly retreating, displaying a classic sell-the-news pattern following the prior session's strong rally.

On July 15, the company announced that its core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) combined with Merck's pembrolizumab met the primary endpoint in the Phase III OptiTROP-Lung06 study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC — the first globally positive ADC plus immunotherapy Phase III result in this patient population. The stock surged over 11% on that day. Goldman Sachs maintained a Buy rating on the stock following the data release.

Broader biotech sector weakness compounded selling pressure, with INNOVENT BIO down 2.42%, AKESO down 1.16%, and 3SBIO down 1.05%, reflecting subdued sector sentiment that amplified the pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108708574?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108708574","market":"us","top_or_hot":-1,"title":"Movement Alert｜Kelun-Biotech Falls 3.45% in Regular Trading, Profit-Taking After Prior Session Clinical Data Rally","media":"Market Focus","content":"<p><p>On July 16, Kelun-Biotech (06990.HK) declined 3.45% in regular trading, trading at HK$519.5/share, with turnover of HK$125 million. The stock opened up over 4% before rapidly retreating, displaying a classic sell-the-news pattern following the prior session's strong rally.</p><p>On July 15, the company announced that its core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) combined with Merck's pembrolizumab met the primary endpoint in the Phase III OptiTROP-Lung06 study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC — the first globally positive ADC plus immunotherapy Phase III result in this patient population. The stock surged over 11% on that day. Goldman Sachs maintained a Buy rating on the stock following the data release.</p><p>Broader biotech sector weakness compounded selling pressure, with INNOVENT BIO down 2.42%, AKESO down 1.16%, and 3SBIO down 1.05%, reflecting subdued sector sentiment that amplified the pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Kelun-Biotech Falls 3.45% in Regular Trading, Profit-Taking After Prior Session Clinical Data Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Kelun-Biotech Falls 3.45% in Regular Trading, Profit-Taking After Prior Session Clinical Data Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, Kelun-Biotech (06990.HK) declined 3.45% in regular trading, trading at HK$519.5/share, with turnover of HK$125 million. The stock opened up over 4% before rapidly retreating, displaying a classic sell-the-news pattern following the prior session's strong rally.</p><p>On July 15, the company announced that its core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) combined with Merck's pembrolizumab met the primary endpoint in the Phase III OptiTROP-Lung06 study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC — the first globally positive ADC plus immunotherapy Phase III result in this patient population. The stock surged over 11% on that day. Goldman Sachs maintained a Buy rating on the stock following the data release.</p><p>Broader biotech sector weakness compounded selling pressure, with INNOVENT BIO down 2.42%, AKESO down 1.16%, and 3SBIO down 1.05%, reflecting subdued sector sentiment that amplified the pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1108708574","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108708574","pubTimestamp":1784167581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, Kelun-Biotech (06990.HK) declined 3.45% in regular trading, trading at HK$519.5/share, with turnover of HK$125 million. The stock opened up over 4% before rapidly retreating, displaying a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"走势预警|科伦生物常规交易跌3.45%，前一交易日临床数据反弹后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On July 16, Kelun-Biotech (06990.HK) declined 3.45% in regular trading, trading at HK$519.5/share, with turnover of HK$125 million. The stock opened up over 4% before rapidly retreating, displaying a classic sell-the-news pattern following the prior session's strong rally.On July 15, the company announced that its core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) combined with Merck's pembrolizumab met the primary endpoint in the Phase III OptiTROP-Lung06 study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC — the first globally positive ADC plus immunotherapy Phase III result in this patient population. The stock surged over 11% on that day. Goldman Sachs maintained a Buy rating on the stock following the data release.Broader biotech sector weakness compounded selling pressure, with INNOVENT BIO down 2.42%, AKESO down 1.16%, and 3SBIO down 1.05%, reflecting subdued sector sentiment that amplified the pullback.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108708574","isCrawlerRequest":true}